Gyre Therapeutics is trading 9.73% up at $4.41, with the earnings beat the clearest company-specific catalyst. - Results released November 5 showed revenue of $32.9 million topping estimates and EPS of -$0.04 beating the analyst estimate of -$0.0733. - The company reaffirmed 2026 revenue guidance of $100.5 million to $111.0 million. Shares closed November 5 at $4.01, down 9.68%. - Broader market sentiment is positive, while the biotech sector is reported down; intraday volume was not provided.